3-[4-(4-tert-butyl-2,6-dimethyl-3,5-dinitrophenyl)(1,3-thiazol-2-yl)amino]phenol | 365223-58-1

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 3-[4-(4-tert-butyl-2,6-dimethyl-3,5-dinitrophenyl)(1,3-thiazol-2-yl)amino]phenol
• 英文别名: 3-[[4-(4-Tert-butyl-2,6-dimethyl-3,5-dinitrophenyl)-1,3-thiazol-2-yl]amino]phenol
• CAS: 365223-58-1
• 化学式: C₂₁H₂₂N₄O₅S
• 分子量: 442.495
• InChiKey: XQQYYSBJPSSXFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.2
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  165
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20010044545A1

  公开（公告）日：2001-11-22

  The present invention relates to the use of aminothiazole derivatives of Formula I of as inhibitors of PAI-1, and to novel classes of aminothiazole derivatives, their synthesis and their use as inhibitors of PAI-1. It has been discovered that compounds of Formula I: 1 or a solvate, hydrate or a pharmaceutically acceptable salt thereof, wherein Y, Ar 1 , Ar 2 , R 1 , R 2 , Z, m and n are described in the specification, inhibit plasminogen activator inhibitor-1 (PAI-1). These compounds can be used in the prophylaxis or for the treatment of thrombosis, angina pectoris, cerebral infarction, myocardial infarction, pulmonary infarction, intra-atrial thrombus in atrial fibrillation, deep venous thrombus, disseminated intravascular coagulation syndrome, diabetic complications, restenosis and stroke.

  本发明涉及使用公式I的氨基噻唑衍生物作为PAI-1的抑制剂，以及新型氨基噻唑衍生物类、它们的合成和作为PAI-1抑制剂的应用。发现公式I的化合物：1或其溶剂化物、水合物或药学上可接受的盐，其中Y、Ar1、Ar2、R1、R2、Z、m和n在说明书中有所描述，能够抑制纤溶酶原激活抑制剂-1（PAI-1）。这些化合物可用于预防或治疗血栓形成、心绞痛、脑梗死、心肌梗死、肺梗死、房颤中的心房内血栓、深静脉血栓、弥散性血管内凝血综合征、糖尿病并发症、再狭窄和中风。
• US6586453B2
  申请人：——

  公开号：US6586453B2

  公开（公告）日：2003-07-01
• [EN] SUBSTITUTED THIAZOLES AND THE USE THEREOF AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1<br/>[FR] THIAZOLES SUBSTITUES ET UTILISATION ASSOCIEE EN TANT QU'INHIBITEURS DE L'INHIBITEUR-1 D'ACTIVATEUR DE PLASMINOGENE
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2001074793A2

  公开（公告）日：2001-10-11

  The present invention relates to the use of aminothiazole derivatives of Formula (I) of as inhibitors of PAI-1, and to novel classes of aminothiazole derivatives, their synthesis and their use as inhibitors of PAI-1. It has been discovered that compounds of Formula (I): or a solvate, hydrate or a pharmaceutically acceptable salt thereof, wherein Y, Ar?1, Ar2, R1, R2¿, Z, m and n are described in the specification, inhibit plasminogen activator inhibitor-1 (PAI-1). These compounds can be used in the prophylaxis or for the treatment of thrombosis, angina pectoris, cerebral infarction, myocardial infarction, pulmonary infarction, intra-atrial thrombus in atrial fibrillation, deep venous thrombus, disseminated intravascular coagulation syndrome, diabetic complications, restenosis and stroke.